Considering the established efficacy of IFN-β as a therapeutic intervention for MS2 and the role of RNF213 as an inducer of IFN-I32,33, we aimed to investigate the potential involvement of RNF213 in IFN-β therapy for MS. This evidence concerns the gene IFNB1 and myeloid sarcoma.